Oxidopamine hydrobromide (Standard)
Oxidopamine hydrobromide (Standard) is the analytical standard of Oxidopamine hydrobromide (HY-B1081A). This product is intended for research and analytical applications. Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytoKine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of ParKinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome.
For research use only. We do not sell to patients.
- CAS No.: 636-00-0
- Formula: C8H12BrNO3
- Molecular Weight:250.09
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 636-00-0
-
Molecular Weight 250.09
-
Formula C8H12BrNO3
-
SMILES
OC1=CC(CCN)=C(O)C=C1O.[H]Br
-
Synonyms
6-Hydroxydopamine hydrobromide (Standard); 6-OHDA hydrobromide (Standard)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Kang X, et al. Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype. Sci Rep. 2017 Aug 25;7(1):9459. [Content Brief]
[2]. Jin F, et al. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur J Pharmacol. 2008 Dec 14;600(1-3):78-82. [Content Brief]
[3]. Fujita H et al. Cell-permeable cAMP analog suppresses 6-hydroxydopamine-induced apoptosis in PC12 cells through the activation of the Akt pathway. Brain Res. 2006 Oct 3;1113(1):10-23. [Content Brief]
[4]. Soto-Otero R et al. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J Neurochem. 2000 Apr;74(4):1605-12. [Content Brief]
[5]. Jin F, et al. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats[J]. European journal of pharmacology, 2008, 600(1-3): 78-82. [Content Brief]
[7]. Ryan RE, et al. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. Br J Pharmacol. 2001 Apr;132(8):1650-6. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Oxidopamine hydrobromide (Standard) Related Classifications
HY-B1081AR Related Classifications
Powered by Bioz
Keywords
- Oxidopamine hydrobromide (Standard)
- 636-00-0
- 6-Hydroxydopamine hydrobromide (Standard)
- 6-OHDA hydrobromide (Standard)
- Reference Standards
- Dopamine Receptor
- Autophagy
- Mitophagy
- COX
- PGE synthase
- Interleukin Related
- p38 MAPK
- Apoptosis
- Caspase
- neurotoxicity
- Parkinson’s disease
- Neuro-2a cells
- SH-SY5Y cells
- attention-deficit hyperactivity disorder
- Lesch-Nyhan syndrome
- PC12 cells
- p-p38
- PGE2
- Inhibitor
- inhibitor
- inhibit